BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 19432122)

  • 1. [Multiple myeloma].
    Abe M
    Nihon Rinsho; 2009 May; 67(5):991-5. PubMed ID: 19432122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New development in bisphosphonate treatment. Treatment with bisphosphonates for cancer-induced bone disease].
    Abe M
    Clin Calcium; 2009 Jan; 19(1):55-62. PubMed ID: 19122265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical management update: multiple myeloma.
    Stoopler ET; Vogl DT; Stadtmauer EA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 May; 103(5):599-609. PubMed ID: 17291793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Supportive care in multiple myeloma for continuing anti-myeloma therapies].
    Shibayama H
    Rinsho Ketsueki; 2014 Oct; 55(10):1999-2004. PubMed ID: 25297765
    [No Abstract]   [Full Text] [Related]  

  • 5. [Bisphosphonates for myeloma patients].
    Miwa A
    Nihon Rinsho; 2007 Dec; 65(12):2315-37. PubMed ID: 18069279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates.
    Kraj M; Pogłód R; Maj S; Owczarska K
    Acta Pol Pharm; 2006; 63(5):450-2. PubMed ID: 17357613
    [No Abstract]   [Full Text] [Related]  

  • 7. Bisphosphonates--role in cancer therapies.
    Mehrotra B
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811
    [No Abstract]   [Full Text] [Related]  

  • 8. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
    J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
    Hoff AO; Toth B; Hu M; Hortobagyi GN; Gagel RF
    Ann N Y Acad Sci; 2011 Feb; 1218():47-54. PubMed ID: 20946574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonate-associated osteonecrosis of the jaw: conclusions based on an analysis of case series.
    Landesberg R; Wilson T; Grbic JT
    Dent Today; 2006 Aug; 25(8):52, 54-7. PubMed ID: 16925161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why osteonecrosis of the jaw after bisphosphonates treatment is more frequent in multiple myeloma than in solid tumors.
    Delibasi T; Altundag K; Kanlioglu Y
    J Oral Maxillofac Surg; 2006 Jun; 64(6):995-6. PubMed ID: 16713825
    [No Abstract]   [Full Text] [Related]  

  • 12. Complication related to bisphosphonate therapy: osteonecrosis of the jaw.
    Lee J
    J Infus Nurs; 2009; 32(6):330-5. PubMed ID: 19918142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates.
    Lobato JV; Rodrigues JM; Cavaleiro MV; Lobato JM; Xavier L; Santos JD; Maurício AC
    Acta Med Port; 2007; 20(2):185-92. PubMed ID: 17868526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteonecrosis and bisphosphonates in oral and maxillofacial surgery.
    Chaudhry AN; Ruggiero SL
    Oral Maxillofac Surg Clin North Am; 2007 May; 19(2):199-206, vi. PubMed ID: 18088878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Osteonecrosis of the jaw associated with the use of bisphosphonates in multiple myeloma: report of four cases and literature review].
    Li LH; Wu XB; Chen WM; Chen JX; Wu Y; Chen SL
    Zhonghua Yi Xue Za Zhi; 2008 Nov; 88(42):2986-7. PubMed ID: 19080077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of zoledronic-acid-induced jaw osteonecrosis with bortezomib.
    Timurağaoğlu A; Ozkaynak C; Tuzuner S; Bostan F; Undar L
    Acta Haematol; 2007; 118(4):203-4. PubMed ID: 17992010
    [No Abstract]   [Full Text] [Related]  

  • 17. Bisphosphonate-induced osteonecrosis of the jaw: long-term outcomes.
    Katz J; George T; Sandow P; Machado M; Dickerson L; Moreb JS
    J Support Oncol; 2009; 7(1):9-10. PubMed ID: 19278171
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple myeloma.
    Altundag K; Altundag O; Gundeslioglu O
    N Engl J Med; 2005 Feb; 352(8):840-1; author reply 840-1. PubMed ID: 15728824
    [No Abstract]   [Full Text] [Related]  

  • 19. Bisphosphonate-related osteonecrosis: genetic and acquired risk factors.
    Sarasquete ME; González M; San Miguel JF; García-Sanz R
    Oral Dis; 2009 Sep; 15(6):382-7. PubMed ID: 19413677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients.
    Favia G; Pilolli GP; Maiorano E
    J Rheumatol; 2009 Dec; 36(12):2780-7. PubMed ID: 19884275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.